San Diego-based BioAtla is cutting approximately 70% of its workforce as it explores strategic options including asset sales, licensing transactions, and strategic partnerships for its pipeline of antibody therapeutics targeting solid tumors.
San Diego-based BioAtla is cutting approximately 70% of its workforce as it explores strategic options including asset sales, licensing transactions, and strategic partnerships for its pipeline of antibody therapeutics targeting solid tumors.